Publications

Publications Reflecting European Collaborative Research

1: Herrmann AB, Müller ML, Orth MF, Müller JP, Zernecke A, Hochhaus A, Ernst T, Butt E, Frietsch JJ. Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance. J Cell Mol Med. 2020 Mar;24(5):2942-2955. doi: 10.1111/jcmm.14910. Epub 2020 Jan 19. PMID: 31957290; PMCID: PMC7077607.

2: Metzgeroth G, Schwaab J, Naumann N, Jawhar M, Haferlach T, Fabarius A, Hochhaus A, Hofmann WK, Cross NCP, Reiter A. Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. Blood Adv. 2020 Feb 11;4(3):440-443. doi: 10.1182/bloodadvances.2019001111. PMID: 31995156; PMCID: PMC7013256.

3: Butt E, Stempfle K, Lister L, Wolf F, Kraft M, Herrmann AB, Viciano CP, Weber C, Hochhaus A, Ernst T, Hoffmann C, Zernecke A, Frietsch JJ. Phosphorylation- Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia. Cells. 2020 Feb 14;9(2):444. doi: 10.3390/cells9020444. PMID: 32075106; PMCID: PMC7072741.

4: Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3. PMID: 32127639; PMCID: PMC7214240.

5: Kaiser A, Schmidt M, Huber O, Frietsch JJ, Scholl S, Heidel FH, Hochhaus A, Müller JP, Ernst T. SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders. Leukemia. 2020 Aug;34(8):2206-2216. doi: 10.1038/s41375-020-0803-3. Epub 2020 Mar 25. PMID: 32214204; PMCID: PMC8318878.

 6: Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Gurnani R, Saglio G. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020 Aug;34(8):2064-2073. doi: 10.1038/s41375-020-0805-1. Epub 2020 Apr 7. PMID: 32265500; PMCID: PMC7387297.

 7: Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, Apperley J. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020 Jun;34(6):1495-1502. doi: 10.1038/s41375-020-0842-9. Epub 2020 May 4. PMID: 32366938; PMCID: PMC7266739.

8: Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M; SAKK and the German CML Study Group. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020 Aug;34(8):2074-2086. doi: 10.1038/s41375-020-0826-9. Epub 2020 May 7. Erratum in: Leukemia. 2020 Oct;34(10):2823. PMID: 32382082; PMCID: PMC7387244.

9: Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, Bardy- Bouxin N, Viqueira A, Leip E, Russell-Smith TA, Leone J, Rosti G, Watts J, Giles FJ; BYOND Study Investigators. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020 Aug;34(8):2125-2137. doi: 10.1038/s41375-020-0915-9. Epub 2020 Jun 22. PMID: 32572189; PMCID: PMC7387243.

10: Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, Guilhot F, Heibl S, Hehlmann R, Faber E, Turkina A, Ossenkoppele G, Höglund M, Zaritskey A, Griskevicius L, Olsson-Strömberg U, Everaus H, Koskenvesa P, Labar B, Sacha T, Zackova D, Cervantes F, Colita A, Zupan I, Bogdanovic A, Castagnetti F, Guilhot J, Hasford J, Hochhaus A, Hoffmann VS. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020 Aug;34(8):2138-2149. doi: 10.1038/s41375-020-0931-9. Epub 2020 Jun 29. PMID: 32601376; PMCID: PMC7387299.

11: Rinke J, Chase A, Cross NCP, Hochhaus A, Ernst T. EZH2 in Myeloid Malignancies. Cells. 2020 Jul 8;9(7):1639. doi: 10.3390/cells9071639. PMID: 32650416; PMCID: PMC7407223.

12: Ernst P, Press AT, Fischer M, Günther V, Gräfe C, Clement JH, Ernst T, Schubert US, Wotschadlo J, Lehmann M, Enzensperger C, Bauer M, Hochhaus A. Polymethine Dye-Functionalized Nanoparticles for Targeting CML Stem Cells. Mol Ther Oncolytics. 2020 Jul 25;18:372-381. doi: 10.1016/j.omto.2020.07.007. PMID: 32913887; PMCID: PMC7452122.

13: Rinke J, Hochhaus A, Ernst T. CML - Not only BCR-ABL1 matters. Best Pract Res Clin Haematol. 2020 Sep;33(3):101194. doi: 10.1016/j.beha.2020.101194. Epub 2020 Jun 7. PMID: 33038988.

14: Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7. Erratum in: Leukemia. 2021 Jul;35(7):2142-2143. PMID: 33414482; PMCID: PMC7862065.

15: Schäfer V, White HE, Gerrard G, Möbius S, Saussele S, Franke GN, Mahon FX, Talmaci R, Colomer D, Soverini S, Machova Polakova K, Cross NCP, Hochhaus A, Ernst T. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. J Cancer Res Clin Oncol. 2021 Oct;147(10):3081-3089. doi: 10.1007/s00432-021-03569-8. Epub 2021 Mar 7. PMID: 33677711.

16: Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MTG, García-Gutiérrez JV, Conneally E, le Coutre PD, Gattermann N, Martino B, Saussele S, Giles FJ, Ross DM, Aimone P, Li S, Titorenko K, Saglio G. Treatment- free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021 May;35(5):1344-1355. doi: 10.1038/s41375-021-01205-5. Epub 2021 Mar 11. PMID: 33707652; PMCID: PMC8102196.

17: Loncarevic IF, Toepfer S, Hubold S, Klingner S, Kanitz L, Ellinger T, Steinmetzer K, Ernst T, Hochhaus A, Ermantraut E. Ultra-precise quantification of mRNA targets across a broad dynamic range with nanoreactor beads. PLoS One. 2021 Mar 18;16(3):e0242529. doi: 10.1371/journal.pone.0242529. PMID: 33735175; PMCID: PMC7971518.

18: Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina AG, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garcia-Gutierrez V, Cortes J, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs. Blood. 2021 Aug 18:blood.2020009984. doi: 10.1182/blood.2020009984. Epub ahead of print. PMID: 34407542.

19: Cortes J, Apperley JF, Lomaia E, Moiraghi B, Undurraga MS, Pavlovsky C, Chuah C, Sacha T, Lipton JH, Schiffer CA, McCloskey J, Hochhaus A, Rousselot P, Rosti G, de Lavallade H, Turkina A, Rojas C, Arthur C, Maness LJ, Talpaz M, Mauro MJ, Hall T, Lu V, Srivastava S, Deininger MW. Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial. Blood. 2021 Aug 18:blood.2021012082. doi: 10.1182/blood.2021012082. Epub ahead of print. PMID: 34407543.

20. Machova Polakova K, Zizkova H, Zuna J, Motlova E, Hovorkova L, Gottschalk A, Glauche I, Koblihova J, Pecherkova P, Klamova H, Stastna Markova M, Dsrbova D, Benesova A, Polivkova V, Jurcek T, Zackova D, Mayer J, Ernst T, Mahon FX, Saussele S, Roeder I, Cross NCP, Hochhaus A. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia 2020 Aug; 34(8):2113-2124 doi: 10.1038/s41375-020-0882-1